SynAct (Q4 Update): ADVANCE Fully Recruited - Redeye

Redeye reviews SynAct Pharma's Q4 report. A new European study in respiratory insufficiency was initiated in February. The ADVANCE study was fully enrolled with 246 patients, also in February; this means topline data will be available in Q2 2026, a major catalyst.

Länk till analysen i sin helhet: https://www.redeye.se/research/1151813/synact-q4-update-advance-fully-recruited?utm_source=finwire&utm_medium=RSS